Silence Therapeutics (SLN) AI Stock Analysis

• Market Cap: $238.99M
• Dividend Yield: N/A
• Average Volume (3M): 154.72K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.17
• Revenue Growth: -40.10%
• EPS Growth: -16.60%
• Country: US
• Employees: 116
• Sector: Healthcare
• Sector Strength: 53
• Industry: Biotechnology
• EPS (TTM): -0.20
• Shares Outstanding: 47,230,280
• 10 Day Avg. Volume: 128,171
• 30 Day Avg. Volume: 154,718
• PEG Ratio: 6.62
• Price to Book (P/B): 55.17
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -26.53
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: $37.50
• Price Target Upside: 641.11% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 5

• Rating: 56 Neutral
• Price Target: $5.50 ▲(8.70%Upside)

The overall stock score is affected by strong technical momentum, which is the most positive aspect, balanced by financial performance challenges and valuation difficulties. The lack of profitability and negative equity are significant concerns, necessitating better financial management and strategic planning.

Positive Factors

Advancement of Zerlasiran

Zerlasiran is advancing toward Phase 3 readiness in Lp(a), supported by regulatory alignment across the U.S., EU, and Japan, and active partnering discussions that management characterized as highly engaged.

Commercial Opportunity of Zerlasiran

Zerlasiran's ~100% Lp(a) reduction in clinic, coupled with low dosing frequency/clean safety profile, can render a significant commercial opportunity.

Efficacy and Safety of Divesiran

Divesiran's final PhI update at EHA reinforces a differentiated profile in PV, including robust efficacy/safety and infrequent dosing, that could potentially drive a best-in-class opportunity.

Negative Factors

Divesiran Competitiveness

The placebo-controlled Phase II portion of the SANRECO study will give further insights into its competitiveness with rusfertide on phlebotomy reductions, and divesiran’s Q6W dosing profile is superior here.

Market Competition in PV

Despite PV's increasingly crowded landscape, PV remains a large commercial opportunity given high unmet need, evidenced by significant sales and partnerships.

Market Uncertainty

Silence reported a focused and execution-driven 1Q25, marked by continued advancement across its clinical pipeline, strategic capital discipline, and an extended cash runway into 2028.

Silence Therapeutics Business Overview & Revenue Model

Company Description

Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development of novel ribonucleic acid (RNA) therapeutics in hematology, cardiovascular, and other rare and metabolic indications. The company's platform includes mRNAi GalNAc Oligonucleotide Discovery platform designed to accurately target specific disease-associated genes in the liver. It designs short interfering RNA molecules to harness the body's natural mechanism of RNA interference, and degrading messenger RNA molecules that encode specific targeted disease-associated proteins in a cell. The company is developing various product candidates, including SLN360, which is Phase I clinical trials for the treatment of cardiovascular disease with high lipoprotein; SLN124 that is in Phase I clinical trials for the treatment of non-transfusion dependent thalassemia, and Phase I clinical trials for the treatment of myelodysplastic syndrome; and SLN124 for the treatment of polycythemia vera. It has collaboration agreements with AstraZeneca PLC to discover, develop, and commercialize small interfering RNA therapeutics for the treatment of cardiovascular, renal, metabolic, and respiratory diseases; and Mallinckrodt Pharma IP Trading DAC to develop and commercialize RNAi drug targets designed to silence the complement cascade in complement-mediated disorders. The company also has a collaboration with Hansoh Pharmaceutical Group Company Limited to develop siRNAs for three undisclosed targets leveraging Silence's mRNAi GOLD platform. The company was formerly known as SR Pharma plc and changed its name to Silence Therapeutics plc in May 2007. Silence Therapeutics plc is headquartered in London, the United Kingdom.

How the Company Makes Money

Silence Therapeutics generates revenue through a combination of research and development collaborations, licensing agreements, and milestone payments from its partnerships with other pharmaceutical and biotech companies. The company licenses its proprietary RNA interference technology to partners who utilize it in the development of their own drug candidates. Additionally, Silence Therapeutics may earn royalties from successfully commercialized products that incorporate its technology. Key partnerships with industry leaders contribute significantly to its earnings by providing upfront payments, research funding, and potential future royalties based on product sales. The company's financial model heavily relies on its ability to establish and maintain strategic alliances that leverage its innovative platform.

Silence Therapeutics Financial Statement Overview

Summary

Silence Therapeutics has shown revenue growth, but faces significant profitability and financial stability challenges, with negative equity and ongoing cash flow issues. Strategic financial planning is needed for improvement.

Income Statement

Silence Therapeutics has demonstrated significant revenue growth over the years, with a notable increase from 2023 to 2024. However, the company continues to face challenges with profitability, as evidenced by negative EBIT and net income margins. The consistent negative profit margins highlight a need for enhanced cost management or increased revenue to achieve profitability.

Balance Sheet

The company's balance sheet reveals a concerning negative stockholders' equity as of 2024, indicating financial instability. The debt-to-equity ratio is not favorable due to the negative equity, and although the company maintains substantial cash reserves, the high liabilities present a risk. Improving equity and managing liabilities are critical for financial health.

Cash Flow

Silence Therapeutics has managed significant financing cash flow, which supports its operations despite negative operating cash flow. The free cash flow has been consistently negative, reflecting ongoing cash challenges. However, the company's ability to secure financing offers some operational flexibility. Improving free cash flow is essential for sustainable growth.

Breakdown
TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
26.21M	43.26M	25.38M	17.50M	12.41M	5.48M
	Gross Profit
19.14M	31.45M	15.06M	6.62M	4.96M	1.72M
	EBIT
-69.27M	-63.32M	-49.60M	-48.59M	-45.81M	-35.85M
	EBITDA
-59.80M	-48.99M	-49.78M	-47.88M	-45.42M	-35.53M
	Net Income Common Stockholders
-56.93M	-45.31M	-43.27M	-40.49M	-39.41M	-32.55M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
136.53M	147.33M	54.03M	71.14M	73.54M	37.45M
	Total Assets
185.30M	202.63M	93.82M	107.50M	96.19M	85.97M
	Total Debt
-60.00K	117.00K	272.00K	446.00K	137.00K	341.00K
	Net Debt
-64.95M	-121.21M	-53.76M	-54.37M	-73.40M	-27.11M
	Total Liabilities
-72.56M	68.61M	76.77M	85.43M	87.67M	76.91M
	Stockholders Equity
-112.74M	134.02M	17.05M	22.07M	8.53M	9.06M
Cash Flow		Free Cash Flow
-36.90M	-67.85M	-39.40M	-45.90M	5.47M	-11.29M
	Operating Cash Flow
-17.12M	-67.64M	-39.35M	-45.46M	6.81M	-10.78M
	Investing Cash Flow
-4.55M	-21.97M	16.43M	-16.54M	8.68M	9.62M
	Financing Cash Flow
16.66M	142.09M	25.16M	43.05M	30.71M	15.43M

Silence Therapeutics Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 5.06
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SLN, the sentiment is Positive. The current price of 5.06 is below the 20-day moving average (MA) of 5.33, above the 50-day MA of 4.18, and below the 200-day MA of 8.73, indicating a neutral trend. The MACD of 0.28 indicates Positive momentum. The RSI at 57.24 is Neutral, neither overbought nor oversold. The STOCH value of 22.82 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SLN.

Silence Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
SLN	56 Neutral	$238.99M	―	-99.23%	―	-40.10%	-16.60%
ADCT	56 Neutral	$335.22M	―	123.38%	―	10.49%	47.31%
Sector *	54 Neutral	$5.34B	3.36	-45.10%	3.39%	16.81%	-0.03%
RGLS	52 Neutral	$569.10M	―	-53.82%	―	―	44.85%
FDMT	48 Neutral	$202.44M	―	-32.97%	―	―	―
KRRO	45 Neutral	$125.18M	―	-60.22%	―	―	85.19%
KLRS	28 Underperform	$44.69M	―	-41.96%	―	―	72.12%

Silence Therapeutics Corporate Events

Silence Therapeutics Announces Board Changes and New Director

On May 5, 2025, Silence Therapeutics announced the retirement of James Ede-Golightly from its Board of Directors, effective at the conclusion of the 2025 Annual General Meeting. Ede-Golightly, who has been a key figure in the company’s transition to a Nasdaq-listed entity, will step down as chair of the Remuneration Committee immediately but remain a member until the AGM. Concurrently, Tim McInerney was appointed as a new director and chair of the Remuneration Committee, bringing over 30 years of experience in the pharmaceutical and biotechnology sectors. McInerney’s appointment is seen as a strategic move to strengthen Silence’s position as a leader in the siRNA field and to support its expansion into the U.S. markets.